Business Wire

Alro Optimizes Production with Quintiq to Maintain Regional Dominance

19.12.2017 13:00:00 EET | Business Wire | Press release

Share

Quintiq, a Dassault Systèmes company and global leader in supply chain planning and optimization (SCP&O), announced its partnership with Alro, the largest aluminum smelter in the Central and non-CIS Eastern European region. Quintiq’s solution will provide capacity planning, inventory management and production scheduling support capabilities.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171219005503/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Alro optimizes production with Quintiq to maintain regional dominance (Photo: Business Wire)

A member of the world’s seventh largest aluminum producer Vimetco N.V., Alro aims to increase its delivery performance and production volume while keeping costs low and minimizing scrap. The company also plans to increase its momentum in highly demanding sectors such as aerospace and automotive metals. Quintiq’s supply chain planning and optimization solution will help Alro reach these goals and maintain its regional dominance by providing full visibility over its entire supply chain to enhance delivery performance and maintain high customer satisfaction levels.

“Visibility creates value,” said Dobra Gheorghe, Alro’s General Director. “Quintiq’s streamlined approach to scheduling gives us full visibility of our present situation, enabling us to better anticipate demand, lead time and potential bottlenecks. This allows us to be more resilient against unforeseen disruptions. Increased assurance of on-time in-full deliveries also enables us to maintain the trust and satisfaction of our customers.”

Alro’s first project with Quintiq is expected to go live in early 2018. Alro has set specific goals that it aims to achieve for the duration of the project. These include a reduction in work-in-progress inventory; an increase in throughput; a reduction of power consumption to achieve sustainability goals; and improved delivery performance.

Quintiq’s successful 20-year track record in the metals industry enabled it to develop solutions that can quickly be implemented with minimal customization, yet tailored to fit Alro’s unique processes, rules, requirements and constraints. Quintiq specializes in end-to-end solutions configured to meet the specific needs of its customers. However, its process-specific metals solutions have the added advantage of being a cost-effective option for companies seeking to quickly optimize specific aspects of their operations before expanding to a large-scale, fully-customized solution.

“Quintiq’s extensive expertise and experience in the metals industry has resulted in the development of proven solutions that bring true value to our customers,” said Markus Malinen, Vice President EMEA-Russia at Quintiq. “Our symbiotic relationship with the industry has resulted in solutions that truly fit the metals landscape and are capable of quickly showing tangible results in the real world. We are confident that Alro will soon experience the full benefits of Quintiq’s optimization technology.”

About Alro

Alro is a subsidiary of Vimetco N.V., a global, vertically-integrated primary and processed aluminum producer. Alro is the largest aluminum producer in Continental Europe (excluding Russia and Scandinavia), having an installed production capacity of 265,000 tons per year.

The main markets for the products manufactured by Alro are within the EU (Germany, Hungary, Poland, Greece and Romania). Alro also exports to the USA and Asia. Alro is ISO 9001 certified for quality management and has NADCAP and EN 9100 certificates for aerospace production organizations. Alro’s products adhere to the quality standards for primary aluminum on the LME as well as international standards for flat-rolled products. To learn more, visit alro.ro.

About Quintiq

Every business has its supply chain planning puzzles. Some of those puzzles are large, some are complex and some seem impossible to solve. Since 1997, Quintiq has been solving each of those puzzles using a single supply chain planning and optimization software. Today, industry-leading companies across the globe rely on Quintiq software to plan and optimize workforces, logistics and production. Quintiq is part of Dassault Systèmes (Euronext Paris: #13065, DSY.PA) and has headquarters in the Netherlands and the USA, and offices around the world.

For more information, visit quintiq.com or follow Quintiq on Twitter, Facebook, LinkedIn and YouTube.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Quintiq
North America Enquiries
Katie Kennedy
Gregory FCA
Tel: +1 610 228 2128
quintiq@gregoryfca.com
or
EMEA Enquiries
Richard Ratcliffe
Weber Shandwick
+44 207 067 0846
quintiq@webershandwick.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release

PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.

Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release

Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor

Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release

Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we

Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release

Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner

Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 16:00:00 EEST | Press release

Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug conjugates (ADCs). Central to Araris’ approach is its proprietary AraLinQ™ ADC technology, which enables the creation of stable and site-specific ADCs using standard antibodies with scalable manufacturing

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye